Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Matthew S. Krantz, Jason Kwah, Cosby A. Stone, Elizabeth J. Phillips, Gilbert Ortega, Aleena Banerji, Kimberly G. Blumenthal
Abstract
5%; 95% CI, 4%-6%; low/moderate, 7%; 95% CI, 6%-9%; high, 11%; 95% CI, 7%-15%), anxiolytics/sedatives (no loneliness, 9%; 95% CI, 7%-10%; low/moderate, 12%; 95% CI, 10%-14%; high, 20%; 95% CI, 15%-25%), antidepressants (no loneliness, 14%; 95% CI, 12%-16%; low/moderate, 19%; 95% CI, 16%-21%; high, 27%; 95% CI, 21%-33%), and polypharmacy (no loneliness, 41%; 95% CI, 38%-43%; low/moderate, 44%; 95% CI, 41%-47%; high, 50%; 95% CI, 44%-56%) (Figure ), and there was a nonsignificant trend for opioid use (no loneliness: 7%; 95% CI, 5%-8%; low/moderate, 7%; 95% CI, 6%-9%; high, 10%; 95% CI, 6%
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicineInfectious disease (medical specialty)OutbreakDiseaseFood Allergy and Anaphylaxis ResearchDrug-Induced Adverse ReactionsSARS-CoV-2 and COVID-19 Research